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So who’s going to benefit?
Eliminating such barriers would 
be good news for multinational 
corporations, who would like to be 
able to operate in both the EU and 
the US without the time and 
expense involved in complying 
with different regulatory regimes. 
Many such corporations support 
TTIP.  It will be especially helpful 
for the automotive, chemical, 
pharmaceutical and financial 
services industries.
The deal’s backers say that we’ll 
all benefit in the long run. Their 
economic models predict that this 
liberalisation will eventually add 
more than $100bn a year to the 
combined GDP of the EU and US, 
as well as creating jobs, boosting 
wages, lowering prices and 
increasing choice. But critics say 
these numbers lack credibility 
and amount to no more than a PR 
exercise (see page XX).
And who’s going to lose out?
Many of the regulations that are 
likely to be targeted under TTIP 
are designed to protect health and 
the environment – for example, 
setting safe levels of pesticides in 
food, chemicals in cosmetics, and 
so on. Campaigners fear these will 
be diluted or eliminated, exposing 
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A good deal. But for whom?
the transatlantic trade and Investment Partnership (ttIP) could have a major impact on human 
health and the environment. New Scientist explains what it is – and how it affects you 
So what is TTIP?
It’s a huge trade deal currently 
being negotiated by the European 
Union and the United States. 
Trade between the two blocs 
already amounts to €1 trillion a 
year. If they reach an agreement, 
the deal will cover 45 per cent of 
global GDP, making TTIP the 
largest trade deal ever struck.
Why should I care?
Because it is likely to have an 
impact on your quality of life. The 
agreement is designed to 
stimulate economic activity by 
tearing down “barriers” to trade, 
ostensibly making everybody 
richer. Opponents, however, 
argue that those barriers, far from 
being useless red tape, exist to 
protect the public on issues such 
as health and the environment.
When will it come into force?
We don’t know. Because the talks 
are being carried out behind 
closed doors, and their outcomes 
kept secret, we don’t know how 
advanced they are. Discussions 
started in 2013 with the stated aim 
of concluding next year, but are 
now expected to run until at  
least 2017.
But it’s just another trade deal?
No. Existing trade deals – of which 
there are dozens around the  
world – mostly involve lowering 
taxes on imports and exports, 
collectively known as tariffs. 
TTIP is different. Because tariffs 
are already very low between the 
EU and US, it will focus on “non-
tariff” barriers, which essentially 
means regulations that get in the 
way of trade and investment.  
ordinary people to greater risk for 
no reason other than the interests 
of multinationals. 
Others, however, argue that 
those fears are exaggerated: the 
goal is simply to harmonise the 
way regulatory decisions are 
made and mutually recognise 
“different but equal” approaches 
(see p X). EU and US carmakers, for 
example, operate under different 
safety rules but produce equally 
safe cars. TTIP would make it 
easier for them to sell the same 
cars on both sides of the Atlantic. 
Presumably balance will be struck?
Not necessarily. The deal is also 
likely to include an arbitration 
procedure called ISDS – the 
Investor-State Dispute Settlement 
– that allows companies to sue for 
compensation if a government 
does something that threatens 
their revenues, such as banning a 
product on health grounds, or 
repealing laws allowing 
marketisation of a public service. 
Similar provisions within other 
trade deals have produced some 
remarkable settlements in favour 
of the corporations (see page X).
Is it inevitable? 
This isn’t the first time that the 
US and EU have tried to forge a 
broad trade agreement. The TTIP 
negotiations might fail too. 
But TTIP has wide support from 
governments, and national 
parliaments will only get a brief 
period to scrutinise the deal 
before being asked to ratify it.
And if they do, it’ll be hard to 
call anyone to account. All the 
documentation will be locked 
away for 30 years. 
“ The trade deal matters 
because it is likely to 
impact on wealth, health 
and the environment”
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WHEN it comes to issues such as 
consumer health and the 
environment, Europe and the US 
often appear to be on different 
planets. US farmers grow about 
700,000 square kilometres of GM 
crops, while Europe maintains 
something close to prohibition. 
For more opinion articles, visit newscientist.com/opinion
Harmony rules
Fears of a regulatory “race to the bottom” do not 
stack up, says Tracey Brown 
Beware the empty economic promises of ttIP, 
warn Ferdi de Ville and Gabriel Siles-Brügge
The US maintains that some 
endocrine-disrupting chemicals 
are safe; the European Union is 
seeking more restrictions. On 
these issues and more, the two 
blocs have come to different 
conclusions about how to balance 
risk, benefit and uncertainty. It 
makes trading difficult and this is 
something TTIP aims to resolve.
Europe’s approach is based on a 
“precautionary principle”. In a 
nutshell, that means new 
products and technologies are 
guilty until proven innocent. 
Anti-TTIP campaigners have 
warned that this principle is 
under attack, with negotiators 
preparing to accept the US’s 
generally laxer rules, forcing 
Europeans to swallow weaker 
regulatory protection. 
This is not true. The EU is not 
unique in building precaution 
into regulation – it just has a 
particular way of doing it. Also 
when the EU and the US use such 
arguments to block products, it is 
often for protectionist reasons. 
For that reason, harmonisation 
makes sense. The beneficiaries 
can be more than the corporate 
bogeymen of anti-TTIP activism. 
Who, for example, would defend a 
return to the wasteful and life-
destroying delays of separately 
run clinical trials?
TTIP is intended to focus on 
methods rather than conclusions 
about safety. It is a response to 
years of trade disputes where the 
EU and the US obdurately hit each 
other with conflicting scientific 
assessments. The negotiations are 
designed to put a stop to this: for 
the first time, EU and US 
authorities won’t oppose each 
other’s scientific evidence about 
safety but will develop ways to 
recognise “equivalent” standards 
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SUPPORTERS of TTIP claim the 
agreement will deliver much-
needed growth and jobs. Karel De 
Gucht, the outgoing EU trade 
commissioner, described it as 
“the cheapest stimulus package 
you can imagine”. To UK prime 
modelling, which is used to 
predict how economies will react 
to changes in policy, such as a 
trade agreement. 
CGE is a form of mainstream 
economic modelling that 
assumes all markets are perfectly 
competitive, efficient and in 
equilibrium. Or, in layman’s 
terms, that there is a buyer for 
every product or service, 
including labour. Not only is this a 
poor approximation of reality, but 
CGE models are notoriously open 
to bias. They can easily be 
of assessment.
So these negotiations won’t end 
up destroying the precautionary 
principle, but they could well 
challenge the fact that EU 
regulators use it without clear 
criteria or accountability. This has 
led to a patchwork of contradictory 
decisions about what is tolerable. 
So, for example, neonicotinoid 
pesticides, which may have some 
detrimental effect on bees, are 
banned, while habitat destruction, 
which has clear detrimental 
effects, is not. Under regulations 
for GM crops, assessors are only 
allowed to consider the risks; 
under chemical regulations they 
look at both risks and benefits. No 
one has explained why.
If the TTIP talks deliver clarity 
about how the precautionary 
principle will be applied, then we 
should welcome that as essential 
and overdue, whatever we think 
about trade liberalisation.
TTIP critics are right: there are a 
lot of closed doors in the EU that 
need to be opened. The 
inscrutability of its precautionary 
regulation is one of them.
Tracey Brown is managing director of 
Sense About Science, a charitable trust 
aiming to provide clarity for the public 
on scientific and medical issues
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Commission. They estimate that 
the deal will generate an extra 
€119bn of GDP annually for the 
EU, or €545 for each family of four, 
by 2027 (€95bn in total and €655 
per family in the US).
Not only are these figures very 
modest, they are fundamentally 
misleading. They both exaggerate 
the potential benefit of TTIP and 
downplay its potential costs.
Firstly, much criticism has been 
directed at the kind of modelling 
used. This is known as computable 
general equilibrium (CGE) 
“ Pull quote to go in here 
over seveines like this pull 
quote to go here like this 
pull quote in here”
minister David Cameron it is a 
“once-in-a-generation prize”.
At the centre of this rhetoric lie 
various claims about the economic 
impact of TTIP. These are taken 
from economic models produced 
at the behest of the European 
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expectancy. Economic inequality 
causes health inequalities; 
poverty kills. 
The whole idea that economic 
growth for its own sake is a good 
thing needs to be seriously 
challenged. GDP does not buy 
happiness. 
It is right that there is a growing 
disquiet about these sinister and 
clandestine negotiations. If you 
are not already an advocate for 
TTIP, it is unlikely the benefits will 
be coming your way. If so, you 
should reject it and campaign 
vigorously to ensure it never 
becomes a reality. 
John Middleton is vice president for 
policy at the Faculty of Public Health, 
the specialist UK body for public health
manipulated to obtain the sorts 
of results the researcher wants. 
These biases are evident in the 
TTIP models. They rely on an 
assumption that the deal will 
eliminate half of the non-tariff 
barriers (or at least half of those 
that could, in principle, be 
removed).
The history of EU-US regulatory 
cooperation suggests that this is 
wildly optimistic. The most that 
negotiators have been able to 
agree on in the past are a series of 
modest “mutual recognition 
agreements” of each other’s rules. 
Moreover, the models assume 
such barriers will be eliminated 
across all sectors of the economy, 
generating synergies that will 
promote growth. This, again, is 
optimistic to say the least. 
The figures also hide much that 
is not easily measurable. This 
includes the social impact of trade 
liberalisation, which often leads 
to workers being forced out of 
uncompetitive industries. 
The models do include 
estimates of “job displacement” – 
ranging from 400,000 to 
1.1 million in the EU – but they also 
assume that these workers will be 
seamlessly reallocated to new jobs 
by the market. Experience 
suggests this is not always the case.
Promising growth and jobs and 
justifying the promise with 
economic models has been a 
powerful tool in the past to stifle 
political debate on controversial 
issues. No politician wants to be 
seen as anti-growth and anti-jobs.
It’s time we challenged this 
tactic so that we can have an open 
and constructive discussion of the 
real costs and benefits of TTIP.  n
Ferdi De Ville is assistant professor  
in EU studies at Ghent University,  
Belgium. Gabriel Siles-Brügge is 
lecturer in politics at the University of 
Manchester, UK
THE UK Faculty of Public Health 
will shortly publish a manifesto 
recommending a range of policies 
designed to protect and improve 
public health. These include a 
sugar tax, a minimum price for a 
unit of alcohol, a ban on junk food 
adverising to children and a living 
wage. All are evidence-based. All 
could be torpedoed by TTIP.
TTIP rides rough-shod over 
national law, undermining the 
entitlement of states to legislate 
to protect their citizens. We 
believe it will damage public 
health and make prospects for 
future laws protecting and 
promoting it less likely.
A lot has been written about 
implications for health services 
like our NHS. The fear is that TTIP 
will open them up to private 
commercial interests – but only in 
narrow and profitable areas of 
patient care, putting the most 
vulnerable and least attractive 
patient services at risk.
The government could request 
that the NHS be exempt from 
TTIP, but it has shown no 
inclination to do so (except for the 
ambulance service). Why would 
it? Its stated objective is to open 
the NHS up to competition. 
Assurances from European 
ministers that the NHS is 
protected are groundless; under 
the Investor State Dispute 
Resolution (ISDS) process (see 
page X) any company with a stake 
in the NHS could cry foul, take 
recourse to the dispute process 
and claim compensation if their 
NHS pickings are not to be 
protected indefinitely. 
TTIP also threatens public 
health by potentially weakening 
legislation such as consumer 
safety standards, workers’ rights 
and environmental controls.
Healthy profits?
Promoting trade may boost profits but it doesn’t make 
people healthier or happier, says John Middleton
It could also exert a “chilling” 
effect on future legislation in 
these areas, with the ISDS making 
governments think twice about 
attempting to pass new laws. If a 
future UK government chose, say, 
to accept the evidence and 
implement a minimum unit 
alcohol price, multinational 
drinks companies could demand 
compensation for lost profits.
We are also concerned that TTIP 
will widen existing health 
inequalities. Past evidence 
suggests the benefits of major 
economic change are not spread 
equally. There will be big winners 
– and big losers. Widening income 
inequalities over the past 40 years 
have been accompanied by 
widening gaps in health and life 
“ Not only are the claimed 
economic gains very 
modest, they are also 
fundamentally misleading”
>
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